Education
About Us
Working with TipRanks
Follow Us
NovoCure Ltd (NVCR)
NASDAQ:NVCR
NVCR Analyst Ratings
Moderate Buy
4 Buy
3 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
NVCR Stock 12 Month Forecast
Average Price Target
$26.50
▲(122.50% Upside)
| Highest Price Target$38.00 | Average Price Target$26.50 | Lowest Price Target$11.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
TR | OpenAI - 4o
$11
Hold
-7.64%
Downside
Reiterated
08/19/25
Wells Fargo
$40→$14.5
Hold
21.75%
Upside
Downgraded
07/25/25
H.C. Wainwright
$38
Buy
219.06%
Upside
Reiterated
07/25/25
NovoCure's Strategic Growth and Market Expansion Drive Buy RatingOur Buy rating and $38 price target are based on a discounted cash flow analysis (DCF). In our DCF, we extend our estimates to 2037 and assign a 12% discount rate and -25% terminal value, given that we view Novocure's technology as a platform. We are currently modeling 2L NSCLC with 100% POS, brain mets from NSCLC with 80% POS, and pancreatic cancer with 70%, and have not included other pipeline assets or indications in our valuation.
Leerink Partners
$33
Buy
177.08%
Upside
Reiterated
07/25/25
J.P. Morgan
$28→$25
Hold
109.91%
Upside
Reiterated
07/21/25
Ladenburg Thalmann & Co.
$30
Buy
151.89%
Upside
Initiated
07/08/25
Piper Sandler
$34
Buy
185.47%
Upside
Reiterated
06/27/25
Wedbush
$27
Hold
126.70%
Upside
Reiterated
04/16/25
Evercore ISI
$46→$38
Buy
219.06%
Upside
Reiterated
02/27/25
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
TR | OpenAI - 4o
$11
Hold
-7.64%
Downside
Reiterated
08/19/25
Wells Fargo
$40→$14.5
Hold
21.75%
Upside
Downgraded
07/25/25
H.C. Wainwright
$38
Buy
219.06%
Upside
Reiterated
07/25/25
NovoCure's Strategic Growth and Market Expansion Drive Buy RatingOur Buy rating and $38 price target are based on a discounted cash flow analysis (DCF). In our DCF, we extend our estimates to 2037 and assign a 12% discount rate and -25% terminal value, given that we view Novocure's technology as a platform. We are currently modeling 2L NSCLC with 100% POS, brain mets from NSCLC with 80% POS, and pancreatic cancer with 70%, and have not included other pipeline assets or indications in our valuation.
Leerink Partners
$33
Buy
177.08%
Upside
Reiterated
07/25/25
J.P. Morgan
$28→$25
Hold
109.91%
Upside
Reiterated
07/21/25
Ladenburg Thalmann & Co.
$30
Buy
151.89%
Upside
Initiated
07/08/25
Piper Sandler
$34
Buy
185.47%
Upside
Reiterated
06/27/25
Wedbush
$27
Hold
126.70%
Upside
Reiterated
04/16/25
Evercore ISI
$46→$38
Buy
219.06%
Upside
Reiterated
02/27/25
Best Analysts Covering NovoCure
1 Month
xxx
Success Rate
12/25 ratings generated profit
Average Return
-0.55%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 48.00% of your transactions generating a profit, with an average return of -0.55% per trade.
3 Months
xxx
Success Rate
14/25 ratings generated profit
Average Return
+8.00%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 56.00% of your transactions generating a profit, with an average return of +8.00% per trade.
1 Year
Success Rate
6/16 ratings generated profit
Average Return
-7.76%
reiterated a buy rating last month
Copying Jonathan Chang's trades and holding each position for 1 Year would result in 37.50% of your transactions generating a profit, with an average return of -7.76% per trade.
2 Years
xxx
Success Rate
2/16 ratings generated profit
Average Return
-27.79%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 12.50% of your transactions generating a profit, with an average return of -27.79% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
NVCR Analyst Recommendation Trends
Rating
Apr 25
May 25
Jun 25
Jul 25
Aug 25
Strong Buy
7
5
7
8
7
Buy
0
1
1
1
0
Hold
6
8
13
14
12
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
13
14
21
23
19
Each month's total comprises the sum of three months' worth of ratings.
NVCR Financial Forecast
NVCR Stock Forecast FAQ
What is NVCR’s average 12-month price target, according to analysts?
Based on analyst ratings, NovoCure Ltd’s 12-month average price target is 26.50.
What is NVCR’s upside potential, based on the analysts’ average price target?
NovoCure Ltd has 122.50% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is NVCR a Buy, Sell or Hold?
NovoCure Ltd has a consensus rating of Moderate Buy which is based on 4 buy ratings, 3 hold ratings and 0 sell ratings.
What is NovoCure Ltd’s price target?
The average price target for NovoCure Ltd is 26.50. This is based on 7 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $38.00 ,the lowest forecast is $11.00. The average price target represents 122.50% Increase from the current price of $11.91.
The highest analyst price target is $38.00 ,the lowest forecast is $11.00. The average price target represents 122.50% Increase from the current price of $11.91.
What do analysts say about NovoCure Ltd?
NovoCure Ltd’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 7 Wall Streets Analysts.
How can I buy shares of NVCR?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.